Preclinical assessment of the distribution of maraviroc to potential human immunodeficiency virus (HIV) sanctuary sites in the central nervous system (CNS) and gut-associated lymphoid tissue (GALT)

References

• Abel S, Van der Ryst E, Rosario MC, Ridgway CE, Medhurst CG, Taylor-Worth RJ, Muirhead GJ. Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. British Journal of Clinical Pharmacology 2008; 65(Suppl. 1)5–18
   PubMed Web of Science ®Google Scholar
• Cashion MF, Banks WA, Bost KL, Kastin AJ. Transmission routes of HIV-1 gp120 from brain to lymphoid tissues. Brain Research 1999; 822: 26–33
   PubMed Web of Science ®Google Scholar
• Chun TW, Nickle DC, Justement JS, Meyers JH, Roby G, Hallahan CW, Kottilil S, Moir S, Mican JM, Mullins JI, et al. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. Journal of Infectious Disease 2008; 197: 714–720
   PubMed Web of Science ®Google Scholar
• DeSesso JM, Jacobson CF. Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. Food and Chemical Toxicology 2001; 39: 209–228
   PubMed Web of Science ®Google Scholar
• Fadel H, Temesgen Z. Maraviroc. Drugs of Today 2007; 43: 749–758
   PubMed Web of Science ®Google Scholar
• Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick KPierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Medicine 1999; 5: 512–517
   PubMed Web of Science ®Google Scholar
• Kalkut G. Antiretroviral therapy: an update for the non-AIDS specialist. Current Opinion in Oncology 2005; 17: 479–484
   PubMed Web of Science ®Google Scholar
• Kalvass JC, Maurer TS, Pollack GM. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: Comparison of unbound concentration ratios to in vivo P-glycoprotein efflux ratios. Drug Metabolism and Disposition 2007; 25: 660–666
   Web of Science ®Google Scholar
• Lin JH, Chiba M, Balani SK, Chen I-W, Kwei GY, Vastag KJ, Nishime JA. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. Drug Metabolism and Disposition 1996; 24: 1111–1120
   PubMed Web of Science ®Google Scholar
• Mueller MC, Bogner JR. Treatment with CCR5 antagonists; which patients may have a benefit?. European Journal of Medical Research 2007; 12: 441–452
   PubMed Web of Science ®Google Scholar
• Poles MA, Boscardin WJ, Elliott J, Taing P, Fuerst MMP, McGowan I, Brown S, Anton PA. Lack of decay of HIV-1 in gut-associated lymphoid tissue reservoirs in maximally suppressed individuals. Journal of Acquired Immune Deficiency Syndrome 2006; 43: 65–68
   PubMed Web of Science ®Google Scholar
• Potchoiba MJ, West M, Nocerini MR. Quantitative comparison of autoradioluminographic and radiometric tissue distribution studies using carbon-14 labelled xenobiotics. Drug Metabolism and Disposition 1998; 26: 272–277
   PubMed Web of Science ®Google Scholar
• Shang E, Russell T, McLean S, Bronk BS, Bednar MM, Gibbs MM. Preclinical to clinical evaluation of brain distribution: Correlation between protein binding, CSF and measured receptor occupancy. AAPS J 2006; 8(Suppl. 2)T2035
   Google Scholar
• Shen DD, Artu AA, Adkinson KK. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Advanced Drug Delivery Reviews 2004; 56: 1825–1857
   PubMed Web of Science ®Google Scholar
• Smith DA, Van de Waterbeemd H, Walker DK. Distribution. Pharmacokinetics and metabolism in drug design, 2nd Revd Edn. Methods and Principles in Medicinal Chemistry, R Mannhold, H Kubinyi, G Folkers. Wiley-VCH, Weinheim (Germany) 2006; 31: 55–65
   Google Scholar
• Thomas SA. Anti-HIV drug distribution to the central nervous system. Current Pharmaceutical Design 2004; 10: 1313–1324
   PubMed Web of Science ®Google Scholar
• Ullberg S. The technique of whole-body autoradiography cryosectioning of large specimens. Science Tools, The LKB Instrument Journal 20 [Special Issue on ‘Whole-Body Autoradiography’, editor Elvefeldt O]:2–29 1977
   Google Scholar
• Venkatakrishnan K, Tseng E, Nelson FR, Rollema H, French JL, Kaplan IV, Horner WE, Gibbs MA. Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: Intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures. Drug Metabolism and Disposition 2007; 35: 1341–1349
   PubMed Web of Science ®Google Scholar
• Walker DK, Abel S, Comby P, Muirhead GJ, Nedderman ANR, Smith DA. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metabolism and Disposition 2005; 33: 587–595
   PubMed Web of Science ®Google Scholar
• Wladyslawa D. Metabolism of psychotropic drugs: pharmacological and clinical relevance. Polish Journal of Pharmacology 1995; 47: 367–379
   PubMedGoogle Scholar
• Wood A, Armour D. The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS. Progress in Medicinal Chemistry 2005; 43: 239–271
   PubMedGoogle Scholar
• Woodnutt G, Berry V, Mizen L. Effect of protein binding on penetration of β-lactams into rabbit peripheral lymph. Antimicrobial Agents and Chemotherapy 1995; 39: 2678–2683
   PubMed Web of Science ®Google Scholar